JIANGSU WUZHONG PHARMACEUTICAL DEVELOPMENT CO., LTD.

JiangSu WuZhong Pharmaceutical Development Co., Ltd.

600200

CNE000000YP4

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
10.95 ^CNY	+3.79%		-1.35%	+33.21%

Apr. 24	JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 24	JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

JiangSu WuZhong Pharmaceutical Development Co., Ltd. cancelled the transaction announced on April 25, 2023

January 03, 2024

On January 4, 2024, JiangSu WuZhong Pharmaceutical Development Co., Ltd. cancelled the transaction. The cancellation has been approved at the 1st session of the company?s 10th supervisory board.

Latest news about JiangSu WuZhong Pharmaceutical Development Co., Ltd.

JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. cancelled the transaction announced on April 25, 2023	Jan. 03	CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Jiangsu WuZhong Pharma to Invest 30 Million Yuan in Local Biotech Firm	23-10-26	MT
Wuzhong Pharmaceutical Development's Unit Gets Registration Certificate for Linezolid Sodium Chloride Injection	23-09-18	MT
JiangSu WuZhong Pharmaceutical Development Co., Ltd.(XSSC:600200) added to S&P Global BMI Index	23-09-18	CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. cancelled the transaction announced on November 11, 2021	23-05-17	CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. announced that it expects to receive CNY 1.2 billion in funding from Zhejiang Fuji Holdings Group Co., Ltd. and other investors	23-04-24	CI
Cinkate Medicine Chemical Intermediate Co., Ltd. agreed to acquire 15% stake in Suzhou Changzheng Cinkate Pharmaceutical Co., Ltd. from JiangSu WuZhong Pharmaceutical Development Co., Ltd. for CNY 33 million.	23-01-31	CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-26	CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. cancelled the transaction to acquire 70% stake in Shanghai Weina Cosmetics Co., Ltd., from Weina Hongkong Co., Limited.	22-01-21	CI
Jiangsu Wuzhong Pharmaceutical Group Corporation announced that it expects to receive CNY 340 million in funding from JiangSu WuZhong Pharmaceutical Development Co., Ltd.	22-01-04	CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. announced that it expects to receive CNY 300 million in funding from Suzhou Fuji Suwu Pharmaceutical Technology Partnership Enterprise (Limited Partnership)	21-11-10	CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-28	CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. agreed to acquire 70% stake in Shanghai Weina Cosmetics Co., Ltd., from Weina Hongkong Co., Limited.	21-09-27	CI
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-27	CI
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-27	CI
Jiangsu Wuzhong Industrial Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-30	CI

Chart JiangSu WuZhong Pharmaceutical Development Co., Ltd.

Duration

Period

Chart JiangSu WuZhong Pharmaceutical Development Co., Ltd.

More charts

JiangSu WuZhong Pharmaceutical Development Co Ltd, formerly Jiangsu Wuzhong Industrial Co Ltd, is a China-based company mainly engaged in pharmaceutical business. The Company's business includes pharmaceuticals, chemicals and real estate. Pharmaceutical business mainly involves pharmaceutical research, development, manufacture and sales. Chemical business mainly includes research, development, manufacture and sales of organic pigments, dyes and intermediates. Its main production varieties are used to produce reactive dyes and organic pigments. Real estate business includes commercial housing and affordable housing.

Sector

Pharmaceuticals

Calendar

2024-05-16 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for JiangSu WuZhong Pharmaceutical Development Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.95 CNY

Average target price

12.7 CNY

Spread / Average Target

+15.98%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JIANGSU WUZHONG PHARMACEUTICAL DEVELOPMENT CO., LTD.	+33.21%	1.03B
ELI LILLY AND COMPANY	+26.47%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.33%	352B
MERCK & CO., INC.	+19.35%	332B
ABBVIE INC.	+4.23%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-4.04%	145B

Other Pharmaceuticals